Latest Dilution News

Optiscan Imaging Ltd secured $17.75 million in a fully underwritten equity raise, fueling clinical studies and regulatory preparations for its innovative medical imaging devices. The company also reported progress in international trials and strengthened its cash position to nearly $20 million.

AdAlta Limited has completed the final share issuance under its Investment Agreement with the Meurs Group, securing the full $700,000 investment that bolstered its cellular immunotherapy development.

AdAlta Limited has made significant progress in its 'East to West' cellular immunotherapy strategy, advancing licensing negotiations for its first CAR-T product and raising $1.6 million through placements to bolster its financial position.

Algorae Pharmaceuticals has broadened its commercial footprint in Australia and New Zealand through key licensing agreements, while advancing its AI-driven drug discovery platform and strengthening leadership.

GoldArc Resources has signed a Letter of Intent with Mineral Mining Services to jointly develop the Leonora South gold project, aiming to accelerate production with minimal capital outlay. The deal includes a drill-for-equity arrangement to preserve cash for exploration.

Everest Metals Corporation has partnered with MEGA Resources and Bain Global Resources to fully fund and operate mining at the Mt Dimer Taipan Gold & Silver Project, with production set to begin imminently.

EMVision Medical Devices has expanded its pivotal clinical trial sites, secured a $3 million government grant, and raised $14 million through placement and share purchase plan, positioning itself strongly for upcoming regulatory submissions and commercialisation.

Great Northern Minerals Limited has issued a prospectus for an underwritten offer of up to 10,000 listed options at an exercise price of $0.02 each, aiming to facilitate their quotation and trading on the ASX.

Cambium Bio has locked in a significant R&D tax rebate and forged three strategic partnerships, underpinning its Phase 3 clinical trials for its lead ophthalmology biologic. The company’s recent capital raise further strengthens its runway as it prepares for pivotal trial milestones.

Pantera Lithium has completed the sale of its Smackover Lithium Project to EnergyX for A$40 million, securing cash and stock that bolster its balance sheet and strategic focus on US critical minerals.

Zelira Therapeutics has made significant progress in its HOPE 1 clinical trial program, completing a key FDA submission and securing a $650,000 non-dilutive R&D loan facility to support ongoing development and working capital needs.

Audio Pixels Holdings has raised A$1.25 million through unsecured convertible notes from sophisticated investors, with the Chairman’s company poised to invest up to A$2 million pending shareholder approval. This funding boost aims to extend the company’s working capital runway and support its strategic goals.